[go: up one dir, main page]

BE2011C008I2 - - Google Patents

Download PDF

Info

Publication number
BE2011C008I2
BE2011C008I2 BE2011C008C BE2011C008C BE2011C008I2 BE 2011C008 I2 BE2011C008 I2 BE 2011C008I2 BE 2011C008 C BE2011C008 C BE 2011C008C BE 2011C008 C BE2011C008 C BE 2011C008C BE 2011C008 I2 BE2011C008 I2 BE 2011C008I2
Authority
BE
Belgium
Prior art keywords
relates
present
gene
pcv2
nonpathogenic pcv1
Prior art date
Application number
BE2011C008C
Other languages
French (fr)
Original Assignee
Univ Iowa State Res Found Inc
Virginia Tech Intellectual Properties Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa State Res Found Inc, Virginia Tech Intellectual Properties Inc filed Critical Univ Iowa State Res Found Inc
Publication of BE2011C008I2 publication Critical patent/BE2011C008I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to an immunogenic polypeptide product which is obtainable by expressing infectious chimeric DNA clones of porcine circovirus (PCV). The present invention also relates to corresponding vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone is constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position.
BE2011C008C 2001-12-12 2011-04-29 BE2011C008I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34077501P 2001-12-12 2001-12-12
US42484002P 2002-11-08 2002-11-08
US10/314,512 US7276353B2 (en) 2001-12-12 2002-12-09 Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
PCT/US2002/039646 WO2003049703A2 (en) 2001-12-12 2002-12-11 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof

Publications (1)

Publication Number Publication Date
BE2011C008I2 true BE2011C008I2 (en) 2022-02-02

Family

ID=27405726

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2011C008C BE2011C008I2 (en) 2001-12-12 2011-04-29

Country Status (30)

Country Link
US (1) US7276353B2 (en)
EP (5) EP2264050B1 (en)
JP (1) JP4623964B2 (en)
KR (1) KR101014544B1 (en)
CN (2) CN103536911B (en)
AT (1) ATE487490T1 (en)
AU (3) AU2002362147C1 (en)
BE (1) BE2011C008I2 (en)
BR (1) BRPI0214919B1 (en)
CA (2) CA2784260C (en)
CO (1) CO5590938A2 (en)
CY (3) CY1111167T1 (en)
DE (2) DE60238278D1 (en)
DK (3) DK2264050T3 (en)
ES (3) ES2529726T3 (en)
FR (1) FR11C0014I2 (en)
HR (3) HRP20140002B1 (en)
HU (5) HU228584B1 (en)
LT (1) LT2264050T (en)
LU (1) LU91814I2 (en)
ME (1) ME00126B (en)
MX (1) MXPA04005364A (en)
NL (1) NL300480I2 (en)
NZ (2) NZ567688A (en)
PL (3) PL215058B1 (en)
PT (3) PT2263689E (en)
RS (1) RS51288B (en)
SI (3) SI1487483T1 (en)
TW (1) TWI314580B (en)
WO (1) WO2003049703A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772047B1 (en) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
CN1749397B (en) * 2004-08-18 2010-12-08 金宁一 Bi-recombinant active carrier vaccine of co-expression pig gyrate virus and foot and mouth disease virus
UA95602C2 (en) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Pcv2 immunogenic compositions and methods of producing such compositions
DK2281829T3 (en) 2004-12-30 2015-02-23 Boehringer Ingelheim Vetmed PCV2 immunogenic compositions for use in a method of preventing PCV2 infection
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
CN1328373C (en) * 2005-04-07 2007-07-25 南京农业大学 Porcine circus-virus 2 type recombinant adenovirus and vaccine
AU2006261943B2 (en) * 2005-06-24 2010-12-02 Intervet International B.V. Inactivated chimeric vaccines and related methods of use
BRPI0615862A2 (en) 2005-09-09 2011-05-31 Intervet Int Bv pcv-2 vaccine, and method for manufacturing a vaccine
TWI528970B (en) * 2005-12-29 2016-04-11 百靈佳殷格翰家畜藥品公司 Multivalent pcv2 immunogenic compositions and methods of producing such compositions
WO2007094893A2 (en) * 2005-12-29 2007-08-23 Boehringer Ingelheim Vetmedica, Inc. Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
JP4625485B2 (en) * 2006-09-29 2011-02-02 財団法人大阪産業振興機構 Monoclonal antibody against highly pathogenic avian influenza virus
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PL2481420T3 (en) 2006-12-15 2019-08-30 Boehringer Ingelheim Animal Health USA Inc. Single dose anti-PCV2 pig vaccine
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CA2687026A1 (en) * 2007-05-30 2009-03-05 Wyeth Raccoon poxvirus expressing genes of porcine virus
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009061798A1 (en) 2007-11-06 2009-05-14 Wyeth Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
AU2008343172B2 (en) * 2007-12-21 2015-02-19 Zoetis Services Llc Methods and compositions for immunizing pigs against porcine circovirus
BRPI0821456A2 (en) * 2007-12-31 2015-06-16 Boehring Ingelheim Vetmedica Inc Particle similar to pcv2 orf2 with foreign amino acid insertion
CN101980720A (en) 2008-01-23 2011-02-23 贝林格尔.英格海姆维特梅迪卡有限公司 PCV2 mycoplasma hyopneumoniae immunogenic composition and preparation method thereof
EP2254595A4 (en) * 2008-02-15 2012-12-05 Boehringer Ingelheim Vetmed METHOD AND COMPOSITIONS FOR REDUCING THE EFFECTS OF STOMACH DISEASES
CN102065890B (en) * 2008-04-16 2014-04-02 弗吉尼亚科技知识产权公司 Chimeric porcine circovirus PCV2Gen-1Rep and uses thereof
AR078253A1 (en) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed METHODS TO REDUCE ANTIVIRICAL ACTIVITY IN PCV-2 COMPOSITIONS AND PCV-2 COMPOSITIONS WITH BETTER IMMUNOGENICITY
LT2547770T (en) 2010-03-16 2020-05-11 Virginia Tech Intellectual Properties, Inc. Live attenuated chimeric porcine circovirus vaccine
TWI442935B (en) 2010-12-22 2014-07-01 Sbc Virbac Ltd Porcine Circovirus Type 2, immunological composition containing the same, test kit and application thereof
WO2012091128A1 (en) 2010-12-28 2012-07-05 Ｊｘ日鉱日石エネルギー株式会社 Organic compound hydrogenation device and hydrogenation method
HUP1100470A2 (en) * 2011-08-30 2013-03-28 Mezoegazdasagi Biotechnologiai Kutatokoezpont Nanoparticle-based veterinary vaccine
UA113192C2 (en) 2011-12-06 2016-12-26 IMMUNOGENIC COMPOSITION AGAINST PIG TYPE 2 (PCV2) CIRCULOSIS
UA114503C2 (en) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс PCV AND MYCOPLASMA HYOPNEUMONIA COMBINED VACCINE
UA114504C2 (en) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс PCV, MYCOPLASMA HYOPNEUMONIA AND PRRS COMBINED VACCINE
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
KR102217387B1 (en) * 2013-03-11 2021-02-19 주식회사 중앙백신연구소 Porcine circovirus2 vaccine using recombinant yeast whole cell and manufacturing thereof
HK1225645A1 (en) 2013-09-25 2017-09-15 Zoetis Services Llc Pcv2b divergent vaccine composition and methods of use
WO2015051099A1 (en) 2013-10-02 2015-04-09 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 protein variant and virus like particles composed thereof
CN103602759B (en) * 2013-11-22 2015-09-23 福建省农业科学院畜牧兽医研究所 A kind of PCR-RFLP method distinguishing duck circovirus and goose PCV-II
US10130698B2 (en) 2013-12-03 2018-11-20 Intervet Inc. Vaccine against porcine circo virus type 2
CN109195623A (en) * 2016-03-07 2019-01-11 弗吉尼亚科技知识产权有限公司 2 type of chimeric porcine circovirus type (PCV2) vaccine
CN106497892A (en) * 2016-09-07 2017-03-15 扬州大学 The construction method of the recombinant virus rPCV2 KT3 with KT3 labels
TW202003027A (en) 2018-03-26 2020-01-16 美商百靈佳殷格翰動物保健美國有限公司 Method of producing an immunogenic composition
CN112898435B (en) * 2021-01-14 2023-03-31 山西农业大学 Soluble fusion protein DT390-Cap as well as preparation method and application thereof
AR132581A1 (en) 2023-05-03 2025-07-16 Boehringer Ingelheim Vetmedica Gmbh IMMUNOGENIC COMPOSITION USEFUL FOR SELF-ADMINISTRATION BY PIGS
AR132582A1 (en) 2023-05-03 2025-07-16 Boehringer Ingelheim Vetmedica Gmbh METHOD TO INDUCE AN IMMUNE RESPONSE

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
WO1999029717A2 (en) * 1997-12-11 1999-06-17 University Of Saskatchewan Postweaning multisystemic wasting syndrome virus from pigs
UA78180C2 (en) * 1997-10-03 2007-03-15 Меріаль Porcine circovirus, vaccines and diagnostic reagents
FR2769321B1 (en) 1997-10-03 2001-10-26 Merial Sas NEW PIG CIRCOVIRUSES, VACCINES AND DIAGNOSTIC REAGENTS
FR2781159B1 (en) 1998-07-06 2000-10-06 Merial Sas CIRCOVIRUS VACCINE AND PIG PARVOVIRUS
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2769322B1 (en) 1997-10-03 2002-03-08 Merial Sas NEW PORCINE CIRCOVIRUSES, VACCINES AND DIAGNOSTIC REAGENTS
FR2772047B1 (en) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION
WO1999045956A1 (en) 1998-03-13 1999-09-16 University Of Georgia Research Foundation, Inc. Vaccines against circovirus infections
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
CA2413265A1 (en) 2000-05-03 2001-11-08 University Of Guelph Porcine adenovirus type 5 vector and vaccine
AU2001256582A1 (en) * 2000-05-24 2001-12-03 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
JP2004503234A (en) 2000-06-15 2004-02-05 パーデュー・リサーチ・ファウンデーション Vaccine for congenital tremor in pigs
DE10044648A1 (en) * 2000-09-08 2002-03-21 Aventis Behring Gmbh Process for the propagation or removal of Cirocoviruses from biological material
MY148759A (en) 2001-03-27 2013-05-31 Univ Saskatchewan Methods to culture circovirus
AUPR567401A0 (en) 2001-06-14 2001-07-12 University Of Melbourne, The Circovirus vaccines

Also Published As

Publication number Publication date
EP2264050A2 (en) 2010-12-22
HU228584B1 (en) 2013-04-29
HRP20040626B9 (en) 2016-09-23
US20030170270A1 (en) 2003-09-11
HRP20040626A2 (en) 2006-03-31
ES2694505T3 (en) 2018-12-21
CY1111167T1 (en) 2014-04-09
PT1487483E (en) 2011-02-10
DK2263689T3 (en) 2015-02-02
EP2263689A2 (en) 2010-12-22
EP2264050A3 (en) 2011-04-20
FR11C0014I2 (en) 2022-03-11
WO2003049703A2 (en) 2003-06-19
US7276353B2 (en) 2007-10-02
EP2264050B1 (en) 2018-08-08
MEP17708A (en) 2010-06-10
AU2002362147B2 (en) 2008-03-13
AU2002362147A1 (en) 2003-06-23
AU2008202333A1 (en) 2008-06-19
MXPA04005364A (en) 2004-09-27
EP1487483A4 (en) 2006-02-15
SI1487483T1 (en) 2011-03-31
LU91814I2 (en) 2011-07-04
PL215058B1 (en) 2013-10-31
WO2003049703A8 (en) 2005-12-01
JP2005511075A (en) 2005-04-28
PL395510A1 (en) 2011-12-19
EP1487483B1 (en) 2010-11-10
PL214803B1 (en) 2013-09-30
DE122011100001I1 (en) 2011-09-08
RS51704A (en) 2006-10-27
RS51288B (en) 2010-12-31
CA2784260C (en) 2016-05-17
DK1487483T3 (en) 2011-02-21
HU231162B1 (en) 2021-05-28
CN103536911A (en) 2014-01-29
PL395509A1 (en) 2011-12-19
AU2008202333B2 (en) 2010-11-25
SI2263689T1 (en) 2015-03-31
SI2264050T1 (en) 2018-12-31
AU2002362147C1 (en) 2012-05-17
NZ533256A (en) 2008-06-30
CY2011004I1 (en) 2014-04-09
DK2264050T3 (en) 2018-12-03
DE60238278D1 (en) 2010-12-23
HUS2100036I1 (en) 2021-09-28
HRP20040626B1 (en) 2016-08-26
ME00126B (en) 2010-10-10
HU230576B1 (en) 2017-01-30
BRPI0214919B1 (en) 2015-09-15
HRP20140003A2 (en) 2014-11-07
BR0214919A (en) 2006-05-30
PT2264050T (en) 2018-11-21
HRP20140002B1 (en) 2020-10-16
EP2263690A2 (en) 2010-12-22
CA2469599A1 (en) 2003-06-19
JP4623964B2 (en) 2011-02-02
LT2264050T (en) 2018-11-26
ATE487490T1 (en) 2010-11-15
CN1620310B (en) 2014-11-26
ES2529726T3 (en) 2015-02-25
PT2263689E (en) 2015-02-13
NL300480I2 (en) 2016-11-01
EP2263689A3 (en) 2011-04-20
WO2003049703A3 (en) 2004-09-30
ES2355814T3 (en) 2011-03-31
HUP1300097A2 (en) 2007-12-28
EP3388515A1 (en) 2018-10-17
HUP0501000A2 (en) 2007-12-28
CY2011004I2 (en) 2015-10-07
EP2263690A3 (en) 2011-06-08
CN103536911B (en) 2019-09-13
KR101014544B1 (en) 2011-02-16
CA2469599C (en) 2012-10-23
TWI314580B (en) 2009-09-11
HU231018B1 (en) 2019-11-28
KR20040086243A (en) 2004-10-08
CO5590938A2 (en) 2005-12-30
EP2263689B1 (en) 2014-11-12
HK1151988A1 (en) 2012-02-17
NZ567688A (en) 2009-09-25
CY1121112T1 (en) 2019-12-11
FR11C0014I1 (en) 2011-06-17
CN1620310A (en) 2005-05-25
AU2011200843A1 (en) 2011-03-17
PL374382A1 (en) 2005-10-17
AU2011200843B2 (en) 2012-01-19
TW200307042A (en) 2003-12-01
EP1487483A2 (en) 2004-12-22
HRP20140002A2 (en) 2014-11-07
CA2784260A1 (en) 2003-06-19
HRP20140003B1 (en) 2020-10-16

Similar Documents

Publication Publication Date Title
HUS2100036I1 (en) Chimeric infectious DNA clones, chimeric porcine circoviruses, and their use
WO2005092069A3 (en) Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
HUP0003756A2 (en) Porcine circoviruses, vaccines and diagnostic reagents
PH12020550706A1 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
ZA202105975B (en) Variant aav capsids for intravitreal delivery
WO2000001409A3 (en) Porcine circovirus and parvovirus vaccine
WO2017187277A3 (en) Chimeric porcine circovirus type 2 (pcv2) vaccines
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
UA106587C2 (en) Chimeric porcine circovirus pcv2gen-1rep and its use
EP2155246B1 (en) Production of a homogeneous cell line highly permissive to porcine circovirus type 2 (pcv2) infection
CY1116098T1 (en) CHEMICAL POLYMERIC POLYMERIC CLONES OF SWINE CIRCULATION AND USE OF THESE
WO2024163979A3 (en) Engineered aav polypeptides